Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

Inclusion criteria

• Age >=18 years.
• Histological or cytological documentation of non hematologic, malignant solid tumour.
• Have failed at least one previous therapeutic regimen.
• LIfe expectancy >= 12 weeks.
• ECOG performance status 0 or 1.
• Written, signed and dated informed consent.
• Able and willing to meet all protocol-required treatments, investigations and visits.
• Have adequate organ function.

Exclusion criteria

• Clinically significant non-malignant disease.
• Active CNS metastases.
• Subjects with uncontrolled diabetes.
• History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents
• Concomitant use of aspirin (> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose), heparin within two weeks prior to randomisation, or other anti-platelet drugs.
• History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media.
• Known seropositivity to the human immunodeficiency vies (HIV)
• Women who are pregnant or breast feeding
• Women of child-bearing potential and male subjects who are partners of women of child bearing potential who are unable or unwilling to use effective means of contraception.
• Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.